WO2007135910A1 - ポドフィロトキシン類の高分子結合体 - Google Patents
ポドフィロトキシン類の高分子結合体 Download PDFInfo
- Publication number
- WO2007135910A1 WO2007135910A1 PCT/JP2007/060026 JP2007060026W WO2007135910A1 WO 2007135910 A1 WO2007135910 A1 WO 2007135910A1 JP 2007060026 W JP2007060026 W JP 2007060026W WO 2007135910 A1 WO2007135910 A1 WO 2007135910A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- podophyllotoxins
- polymer
- integer
- polymer conjugate
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 99
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 title claims abstract description 44
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229960001237 podophyllotoxin Drugs 0.000 title claims abstract description 36
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 33
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 29
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920000805 Polyaspartic acid Polymers 0.000 claims abstract description 26
- 108010064470 polyaspartate Proteins 0.000 claims abstract description 23
- 125000002843 carboxylic acid group Chemical group 0.000 claims abstract description 12
- 125000003827 glycol group Chemical group 0.000 claims description 27
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 24
- 229960005420 etoposide Drugs 0.000 claims description 23
- 229920001400 block copolymer Polymers 0.000 claims description 22
- 125000003282 alkyl amino group Chemical group 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 6
- 238000006297 dehydration reaction Methods 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000001302 tertiary amino group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 5
- 229960001278 teniposide Drugs 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108700012359 toxins Proteins 0.000 claims description 5
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims description 2
- 241001495452 Podophyllum Species 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 20
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000003600 podophyllotoxin derivative Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- -1 methinore Chemical group 0.000 description 26
- 229940125904 compound 1 Drugs 0.000 description 21
- 229940125782 compound 2 Drugs 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 13
- 235000003704 aspartic acid Nutrition 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 229940126214 compound 3 Drugs 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 8
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 6
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 150000001510 aspartic acids Chemical class 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229940093181 glucose injection Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 229920002643 polyglutamic acid Polymers 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 2
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000005267 main chain polymer Substances 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 241000894007 species Species 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- PJEXUIKBGBSHBS-UHFFFAOYSA-N 1-(hydroxymethyl)pyrrolidin-2-one Chemical compound OCN1CCCC1=O PJEXUIKBGBSHBS-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004888 n-propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
- C08G73/1092—Polysuccinimides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/05—Polymer mixtures characterised by other features containing polymer components which can react with one another
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
Definitions
- the present invention relates to a polymer of podophyllotoxins in which a carboxylic acid group of a polymer having a polyethylene glycol structure portion and two or more succinic monoamide structure portions and a hydroxyl group of podophyllotoxins are ester-bonded.
- the present invention relates to a bonded body, a manufacturing method thereof and an application thereof. Background art
- Podophyllotoxin is a bioactive substance contained in the water extract from the roots and stems of the perennial Podofilm spp.
- Podophyllotoxin and its derivatives have anti-cancer activity It is known.
- many of these compounds are sparingly soluble in water, and studies have been conducted on water-soluble polymerized derivatives of podophyllotoxins with the aim of further improving the effectiveness.
- Patent Document 1 describes a high-molecular derivative of podophyllotoxin bound with polyethylene glycol.
- this polymer derivative of podophyllotoxin is structurally capable of binding only one or two podophyllotoxin molecules per molecule of polyethylene glycol, so that an effective amount of the drug can be administered. Requires administration of large amounts of polymer.
- Patent Document 2 describes a molecule in which a drug is bound to a block copolymer of polyethylene glycol and polyaspartic acid that forms micelles and exhibits water solubility
- Patent Document 3 describes polyethylene glycols.
- a polymer carrier that is a polymer drug carrier in which a hydrophobic substance is bound to a side chain carboxylic acid of a block copolymer of a polyacidic amino acid and a polyacidic amino acid is described.
- Patent Document 4 describes a polymer derivative of camptothecins in which a side chain carboxylic acid group of a block copolymer of polyethylene glycols and polyglutamic acid is bonded to a phenolic hydroxyl group of camptothecins.
- Patent Documents 2 to 4 describe podophyllum oral toxin conjugates, which are described in detail.
- Patent Document 1 Japanese Patent Publication No. 10-513187
- Patent Document 2 Japanese Patent No. 2694923
- Patent Document 3 Japanese Patent No. 3268913
- Patent Document 4 International Publication No. 2004/39869 Pamphlet
- Podophyllotoxins such as etoposide and teniposide are useful anticancer agents, and there is a need for new derivatives having water solubility and excellent anticancer activity.
- the present inventors have found that when a compound having a hydroxyl group is ester-bonded to a free carboxylic acid having a succinic acid monoamide structure, the succinic acid monoamide is cyclized. When the structure (succinimide) is changed, the compound having a hydroxyl group is likely to be liberated. From this phenomenon, a polymer having a polyethylene glycol structural part and a succinic monoamide structural part and the hydroxyl group of podophyllotoxins Produced a polymer conjugate of podophyllotoxins having an ester bond, and found that the polymer conjugate released podophyllotoxins without depending on hydrolase, thereby completing the present invention.
- the present invention relates to the following (1) to (: 10).
- Rl represents a hydrogen atom or a (C1-C6) alkyl group
- R2 represents a linking group
- R3 represents a hydrogen atom or a (C1-C6) acyl group
- R4 represents a hydroxyl group of podophyllotoxins.
- R5 is a (C1-C30) alkoxy group, (C7-C30) aralkyloxy group, (C1-C30) alkylamino group, di (C1-C30) alkylamino group, carboxy group protected
- An optionally substituted (C1-C5) alkyl group, t is an integer from 5 to 11500, and d, e, ⁇ , g, h, i and j are each independently.
- R1 is a (C1-C6) alkyl group
- R2 is a (C2-C6) alkylene group
- R3 is a (C1-C6) acyl group
- t is an integer of 8-2300
- d , E, f, g, h, i and j are each independently an integer of 0 to 100, where d + e is an integer of 1 to 100, and d + e + f + g + h + i + j is Polymer binding of podophyllotoxins according to (4) above, which is an integer of 6 to 100 body.
- R1 is a (C1-C3) alkyl group
- R2 is a (C2-C4) alkylene group
- R3 is a (C1-C3) acyl group
- t is an integer of 100-300
- d , E, f, g, h, i and j are each independently an integer of 0 to 90, where d + e is an integer of 1 to 90, and d + e + f + g + h + i + j
- An anticancer agent comprising as an active ingredient a polymer conjugate of the podophyllotoxins according to (1) to (8) above.
- the polymer conjugate of the podophyllotoxins of the present invention can release a drug without depending on a hydrolase in a living body, and can be expected to have an effective therapeutic effect hardly affected by individual differences. .
- the polymer conjugate of the podophyllotoxins of the present invention comprises an ester bond between a carboxylic acid group of a polymer having a polyethylene glycol structure portion and two or more succinic monoamide structure portions and a hydroxyl group of the podophyllotoxins. It is characterized by being.
- the succinic acid monoamide structure portion means -HNCO-C-C-CO H structure
- succinic monoamide one HNC ⁇ 1 CH -CH -CO H
- a structure in which one of the two carboxylic acids of laginic acid is amidated one HNC ⁇ 1CH (— N H—) —CH 2 —CO H or HNCO—CH—CH (—NH—) —CO H ) Etc.
- succinic acid monoamide structural portions may constitute the main chain of the polymer such as polyaspartic acid, or polyalcohols such as dextran, polyamines such as polylysine, and polycarboxylic acids other than polyaspartic acid ( For example, it may be bonded to a functional group of a main chain polymer composed of polylactic acid.
- Examples of the polymer having a polyethylene glycol structural part and two or more succinic monoamide structural parts include graft polymers in which a polyethylene glycol structural part and a succinic monoamide structural part are arranged in a comb shape from a main chain polymer, polyethylene glycol Examples thereof include a block polymer (block copolymer) in which a polymer having a structural portion and a succinic acid monoamide structural portion are connected in series.
- the graft polymer includes a polymer in which a polyethylene glycol structural part is partially bonded to the main chain of polyaspartic acid
- the block type polymer also includes a polymer in which the end of polyaspartic acid is bonded to the end of the polyethylene glycol structure.
- Polyethylene glycol structural moiety in the polymer of the polymer conjugate of the podophyllotoxins of the present invention includes polyethylene glycol modified at both ends or one end, and when both ends are modified,
- the modifying groups may be the same or different.
- Examples of the modifying group include (C1-C6) alkyl groups which may have a substituent.
- the alkyl group of the (C1-C6) alkyl group which may have a substituent includes the following alkyl groups, preferably (C1-C4) alkyl groups, such as a methyl group or an ethyl group. N-propyl group, n_butyl group and the like.
- Examples of the substituent of the (C1 to C6) alkyl group which may have a substituent include an amino group, a methylamino group, a dimethylamino group, an ethylamino group, and a jetylamino group.
- the molecular weight of the polyethylene glycol structure is about 300 to 500,000, preferably ⁇ is about 500 to 100,000, and more preferably ⁇ is about 1,000 to 50,000.
- the positive polymer having a polyethylene glycol structure part and two or more succinic acid monoamide structure parts has a molecular weight of about 500 to 600,000, preferably ⁇ is 600 to 10,000. The degree is more preferably about 800 to 80000.
- the molecular weight in the present invention is a weight average molecular weight measured by a GPC method.
- the amount of podophyllotoxins bound to the polymer having a polyethylene glycol structural part and two or more succinic monoamide structural parts is determined by the total number of rubonic acid groups. 1 to: 100%, preferably :! to 90%, more preferably 2 to 60%.
- the podophyllotoxins in the present invention are not particularly limited as long as they have a hydroxyl group and have antitumor activity and are podophyllotoxins.
- the podophyllotoxin include podophyllotoxin represented by the following formula (II), etoposide represented by the following formula (III), teniposide represented by the following formula (IV), and the like.
- the hydroxyl group of podophyllotoxins include the alcoholic hydroxyl group of the following formula (II), the alcoholic hydroxyl group of the sugar moiety of the following formula (III) and the following formula (IV), and the phenolic hydroxyl group of the benzene ring.
- the force S and its replacement position are not limited.
- the polymer conjugate of the podophyllotoxins of the present invention is a conjugate bound by either the alcoholic hydroxyl group of the podophyllotoxins or the phenolic hydroxyl group of the podophyllotoxins, or A mixture thereof may be mentioned, or a podophyllotoxin bonded with an alcoholic hydroxyl group may be mixed with a phenolic hydroxyl group on one molecule of the polymer conjugate.
- the two or more succinic acid monoamide structural moieties are preferably polyaspartic acid.
- the polymer conjugate of the podophyllotoxins of the present invention is preferably the above general formula (I) [wherein R1 represents a hydrogen atom or a (C1-C6) alkyl group, and R2 represents a linking group.
- R3 represents a hydrogen atom or a (C1 to C6) acyl group
- R4 represents a hydroxyl group residue of podophyllotoxins
- R5 represents a (C1 to C30) alkoxy group, (C7 to C30) aralkyloxy group , (Cl-C30) anolequinolamino group, di (C1-C30) alkylamino group, amino acid with protected carboxy group and —N (R6) CONH (R7) force
- R6 and R7 are (C3-C6) which may be the same or different, (C1-C5) alkyl group optionally substituted with a cyclic alkyl group or a tertiary amino group
- t represents an integer of 5 to: 11500
- d, e, f, g, h, i and j each independently represent an integer from 0 to 200, where d + e represents an integer from 1 to 200, and d + e + f + g
- the (C1-C6) alkyl group in R1 of the general formula (I) includes a linear or branched (C1-C6) alkyl group such as a methinore group, an ethyl group, an n-propyl group, i- Examples include propyl group, n-butyl group, t_butyl group, n_pentyl group, i_pentyl group, n_hexyl group, etc., and linear or branched (C1-C4) alkyl groups are preferred. Even more preferred are methyl groups, particularly preferred are straight-chain or branched (C 1 -C 3) alkyl groups such as methinore, ethyl, n-propyl and i-propyl.
- Examples of the linking group represented by R2 in the general formula (I) include, but are not limited to, (C2 to C6) alkylene groups, and (C2 to C4) alkylene groups are preferred. , Ethylene group, trimethylene group, butylene group and the like, and trimethylene group is particularly preferable.
- the (C1-C6) acyl group in R3 of the general formula (I) is not particularly limited, and examples thereof include a formyl group, a acetyl group, a propionyl group, a bivaloyl group, and the like (C1-C 3 )
- An acyl group is preferred, and an acetyl group is particularly preferred.
- Examples of the podophyllotoxins in the hydroxyl residue of the podophyllotoxins represented by R4 in the general formula (I) include the podophyllotoxins described above, and the carboxylic acid portion of the polymer and the dehydrating condensing agent. It is not particularly limited as long as it is a podophyllotoxin having a hydroxyl group having an ester bond and having antitumor activity.
- Examples of the podophyllotoxins include podophyllotoxin represented by the above formula (II), etoposide represented by the above formula (III), teniposide represented by the above formula (IV), and the like. Can be mentioned.
- R5 in the general formula (I) is a (C1-C30) alkoxy group, a (C7-C30) aralkyloxy group,
- Examples of the (C1-C30) alkoxy group include a linear or branched (C1-C30) alkoxy group, and a linear or branched (C1-C10) alkoxy group is preferred.
- a methoxy group, an ethoxy group, an n-propoxy group, an i-propoxy group, an n-butoxy group, a t-butoxy group, and the like (C7 to C30) aralkyloxy group includes a linear or branched (C7 to C7) group.
- C30) aralkyloxy group is exemplified, and a linear or branched (C7 to C12) aralkyloxy group is preferred. Examples thereof include 4_phenylbutoxy group.
- the (C1-C30) alkylamino group or di (C1-C30) alkylamino group includes a linear or branched (C1-C30) alkylamino group or di (C1-C30) alkylamino group.
- linear or branched (C1-C20) alkylamino groups or di (C1-C20) alkylamino groups for example, methylamino group, ethynoleamino group, n-propylamino group, i-propylamino group N-butylamino group, t-butylamino group, dimethylamino group, jetylamino group, di (n-butyl) amino group and the like.
- amino acid in which the carboxy group is protected examples include amino acids in which the force loxy group used in normal peptide synthesis is protected, such as phenylalanine benzyl ester.
- R6 may be the same or different (C3-C6) substituted with a cyclic alkyl group or a tertiary amino group.
- the (C1-C5) alkyl group which may be present] is not particularly limited, and examples thereof include a cyclohexylaminocarbonylcyclohexylamino group and an isopropylaminocarbonylisopropylamino group.
- the polyaspartic acid which is a succinic monoamide structure moiety in the polymer conjugate of the podophyllotoxins represented by the above general formula (I) of the present invention includes an a -amino acid type, ⁇ Forces with constituent units such as amino acid type and cyclized unit
- the order of binding of these constituent units is not limited, and may be block type or random type.
- the total aspartic acid number of polyasparagic acid in the polymer conjugate of podophyllotoxins represented by the above general formula (I) is represented by d + e + f + g + h + i + j, for example, ,block It can be determined from the amount of aspartic acid derivative used in producing the copolymer.
- the aspartic acid number (d + e + f + g + h + i + j) is about 3 to 200, preferably 6
- the ratio of aspartic acid number (d + e) bound by podophyllotoxins to the total aspartic acid number (d + e + f + g + h + i + j) is 1 to 100%, preferably It is 3 to 90%, more preferably 4 to 60%.
- Aspartic acid number (d + e) is about 1 to 200, preferably
- the number of aspartic acids bound to podophyllotoxins (d + e) is, for example, a dehydration condensation reaction in which podophyllotoxins are ester-bonded in an organic solvent as shown in the following examples. After carrying out, it can be determined from the amount of unreacted podophyllotoxins remaining in the reaction solution.
- the ratio of the single amino acid type (d + f + h) to the total aspartic acid number (d + e + f + g + h + i + j) is 10 to 100%, preferably 20 to 100%.
- the ⁇ -amino acid type (e + g + i) ratio is 0 to 90%, preferably 0 to 80%. This ratio can be changed as appropriate by, for example, selecting deprotection conditions for the protecting group of polyaspartic acid.
- t in the above general formula (I) is a force that is an integer of about 5 to 11500, preferably an integer of about 8 to 2300, and more preferably an integer of about 100 to 300.
- the polymer conjugate of the podophyllotoxins of the present invention may form micelles having a polyethylene glycol structure as an outer shell in water.
- the polymer conjugate of the podophyllotoxins of the present invention comprises a polymer having a polyethylene glycol structure part and two or more succinic monoamide structure parts, and a hydroxyl group of the podophyllotoxins in an organic solvent. Obtained by ester bonding using a dehydrating condensing agent, and the production method is also included in the present invention. That is, for example, a block copolymer of a polyethylene glycol structural partial polyaspartic acid prepared by the method described in Patent Document 2 and a podophyllotoxin in which functional groups other than the group to be reacted are protected as necessary.
- N N_dimethylformamide
- DMF 1,3-dimethyl-2-imidazolidinone
- NMP N_methylpyrrolidone
- dipolar solvent 0 to: 180 ° C, preferably 5 to 50 ° C, dicyclohexylcarbodiimi (DCC), Diisopropylcarbodiimide (DIPC), 1-Ethyl-3- (3-Dimethylaminopropyl) carbodiimide hydrochloride (WSC), 1-Ethoxycarbonyl 2-Ethoxy-1, 2-dihydroxyquinolinone (EEDQ) It is a production method that is subjected to a reaction using a dehydration condensing agent.
- a reaction aid such as N, N-dimethylaminopyridine (DMAP) may be used.
- DMAP N, N-dimethylaminopyridine
- R5 may be an -N (R6) CONH (R7) group (R6 and R7 may be the same or different (C3-C6) substituted with a cyclic alkyl group or a tertiary amino group.
- R6 and R7 may be the same or different (C3-C6) substituted with a cyclic alkyl group or a tertiary amino group.
- the polymer conjugate of podophyllotoxins that are (CI to C5) alkyl groups) can also be obtained by a reaction using the above-mentioned carpositimides as a condensing agent.
- R5 in the compound of the general formula (I) is a (C1-C30) alkoxy group, a (C7-C30) aralkyloxy group, a (C1-C30) alkylamino group, a di (C1-C30) alkylamino group or
- a method for introducing an amino acid with a protected carboxyl group the polymer carboxylic acid group is activated and then bound, the amount of the corresponding alcohol, the amino acid with the corresponding amine or carboxy group protected is used as a base.
- a method of reacting under the sexual condition, a method of reacting with the polymer after activating the corresponding alcohol, amino acid with the corresponding amine or carboxy group protected, and the like are possible.
- the unreacted carboxylic acid group in the polymer can be reactivated by the same reaction.
- the hydroxyl group of podophyllotoxins can be condensed here or different alcohol, amine, etc.
- a polymer having various substituents of R5 may be synthesized by repeating the reaction, and then podophyllotoxins may be condensed.
- podophyllotoxins (C1-C30) alkoxy group, (C7-C30) aralkyloxy group, (C1-C30) alkylamino group, di (C1-C30) alkylamino group or carboxy group You may condense protected amino acids, etc.
- the method for producing the polymer conjugate of the podophyllotoxins of the present invention is not limited to the above method.
- the present invention also includes an anticancer agent comprising the polymer conjugate of the podophyllotoxins of the present invention as an active ingredient.
- the polymer conjugate can be used in commonly used dosage forms such as injections, tablets and powders.
- Pharmaceutically acceptable carriers usually used for formulation
- binders, lubricants, disintegrants, solvents, excipients, solubilizers, dispersants, stabilizers, suspending agents, preservatives, soothing agents, pigments, fragrances, etc. can be used. binders, lubricants, disintegrants, solvents, excipients, solubilizers, dispersants, stabilizers, suspending agents, preservatives, soothing agents, pigments, fragrances, etc. can be used. .
- water for example, water, physiological saline, 5% glucose or mannitol solution, water-soluble organic solvent (for example, glycerol, ethanol, dimethyl sulfoxide, N-methylolpyrrolidone, polyethylene glycol, Cremophor or a mixture thereof) or a mixture of water and the water-soluble organic solvent is used.
- water-soluble organic solvent for example, glycerol, ethanol, dimethyl sulfoxide, N-methylolpyrrolidone, polyethylene glycol, Cremophor or a mixture thereof
- the dose of the polymer conjugate of the podophyllotoxins of the present invention can be naturally changed depending on the sex, age, physical condition, disease state, etc. of the patient.
- 0.01 to 500 mgZm 2 preferably 0.:!
- To 250 mgZm 2 is administered as an active ingredient per day.
- Administration by injection is performed intravenously, intraarterially, affected area (tumor area) and the like.
- an isopropylaminocarbonylisopropylamino group can be added as R5, and its abundance ratio is 1 H-NMR (hydrogen nuclear magnetic field) of Compound 1 dissolved in sodium dehydride Z heavy water Z deuteronitrile. (Resonance spectrum), and the proportion of isopropylaminocarbonylisopropylamino group in compound 1 in polyaspartic acid, that is, the ratio of f + g to d + e + f + g + h + i + j It was 19.6%.
- Other aspartic acids are free carboxylic acids (h + i) or cyclic structures 1.
- Compound 2 (a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12000 and a polyspartic acid moiety having a polymerization number of 35 and a podophyllotoxin:
- Rl Me (methyl group) in the general formula (I)
- R2 trimethylene group
- R3 Ac (acetyl group)
- R4 podophyllotoxin residue
- Composition Composition
- a methoxypolyethyleneglycol-polyaspartic acid block copolymer (aspartic acid polymerization number 35, 226 mg) prepared by the method described in Patent Document 3 and a commercially available podophyllotoxin (106 mg) are dissolved in DMF (5 ml).
- DMAP (12 mg) and DIPC (0.16 ml) were added, and the mixture was stirred at 25 ° C. for 20 hours.
- Ethanol (15 ml) and diisopropyl ether (60 ml) were added to the reaction solution and stirred at room temperature for 120 minutes. The precipitate was collected by filtration and ethanol / diisopropyl ether (lZ4 (vZv), 10 ml). Washed with.
- an isopropylaminocarbonylisopropylamino group can be added as R5, and the abundance ratio thereof can be obtained from 1 H-NMR of a compound 2 dissolved in sodium dehydride Z heavy water Z deuteronitrile.
- the proportion of the isopropylaminocarbonyl isopropylamino group in compound 2 in the polyaspartic acid that is, the ratio of f + g to d + e + f + g + h + i + j was 15.2%.
- Other aspartic acids are free carboxylic acids (h + i) or cyclic structures 1.
- Compound 3 (a conjugate of a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12000 and a polyspartic acid moiety having a polymerization number of 33 and podophyllotoxin:
- Rl Me (methyl group) in the general formula (I)
- R2 trimethylene group
- R3 Ac (acetyl group)
- R4 podophyllotoxin residue
- Methoxypolyethyleneglycol-polyaspartic acid block copolymer (aspartic acid polymerization number 33, 464.4 mg) prepared by the method described in Patent Document 3 and commercially available podophyllotoxin (lOOmg) in DMF (6 ml) Dissolve in DMAP (12 mg) and DIPC (0 • 09 ml) and stir at 15 ° C. for 20 hours. Subsequently, the feluranalan benzyl ester nore hydrochloride (36.8 mg), triethinoreamine (0.02 ml) and DIPC (0.23 ml) were calored and stirred at 15 ° C for another 20 hours, then 25 more. The mixture was stirred at ° C for 4 hours.
- the 0-benzylphenylalanyl group introduced as one of R5 is obtained by hydrolyzing compound 3 in aqueous solution of sodium acetate nitrile monohydroxide at 40 ° C for 6 hours and quantifying the eluted benzyl alcohol.
- the proportion of benzyl-phenylalanyl group in polyaspartic acid, that is, f + g harm to d + e + f + g + h + i + j IJ total is: benzyl benzylalanyl It was 13% when the group was bonded.
- isopropylaminocarbonylisopropylamino group was also introduced as R5, and the existence ratio was determined by 1 H-NMR (hydrogen nuclear magnetic resonance spectrum) force of compound 3 dissolved in sodium dehydride Z heavy water Z deuteronitrile. It is done.
- Isopropylaminocarbonyl The proportion of isopropylamino groups in polyaspartic acid, that is, the ratio of f + g to d + e + f + g + h + i + j 15%.
- the ratio of the total amount of R5 to the polyaspartic acid that is, the ratio of f + g to d + e + f + g + h + i + j was 28%.
- Other aspartic acids are free carboxylic acids (h + i) or cyclic structures (j).
- Comparative Compound 1 (a conjugate of etoposide with a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12000 and a polygnoretamic acid moiety having a polymerization number of 23 and prepared by the method described in JP-A-5-955 Methoxypolyethylenedalicol-polyglutamic acid block copolymer (21 mg) and commercially available etoposide (9.6 mg) are dissolved in DMF (lml), DMAP (0.6 mg) and DIPC (0.01 ml) are added, and 25 ° The mixture was stirred at C for 20 hours.
- Comparative Compound 2 conjugate of podophyllotoxin and a block copolymer consisting of a methoxypolyethylene glycol moiety having a molecular weight of 12000 and a polygnoretamic acid moiety having a polymerization number of 23
- a methoxypolyethylenedalicol-polyglutamic acid block copolymer (52 mg) prepared by the method described in JP-A-5-955 and a commercially available podophyllotoxin (10 mg) are dissolved in DMF (lml), and DMAP (2 mg), DIPC (0.03 ml) was added and 25. The mixture was stirred at C for 20 hours. Ethanol (3 ml) and diisopropyl ether (12 ml) were added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes. The precipitate was collected by filtration and washed with ethanol / diisopropyl ether (1/4 (v / v), 2 ml). Washed.
- Compound 1 or Comparative Compound 1 was dissolved in PBS (phosphate buffered saline; pH 7.1) at a polymer concentration of lmgZml and incubated at 37 ° C. Etoposide released from the polymer conjugate was separated by HPLC and quantified using a standard curve. Figure 1 shows the ratio between the quantitative value and the drug content of the polymer conjugate.
- the polymer conjugate of the present invention (Compound 1) releases more than 85% etoposide in 24 hours even without hydrolase, whereas the succinic acid monoamide structure moiety Comparative compound 1, which does not have, hardly releases etoposide even in 24 hours. This result indicates that the polymer conjugate of etoposides of the present invention has excellent drug release performance in the absence of an enzyme.
- Compound 2, 3 or comparative compound 2 PBS (phosphate buffered saline;. P H7 1) was dissolved in lmgZml a polymer one concentration, and incubated at 37 ° C. The podophyllotoxin released from the polymer conjugate was separated by HPLC and quantified using a standard curve. Fig. 2 shows the ratio between the quantitative value and the drug content of the polymer conjugate.
- PBS phosphate buffered saline
- the polymer conjugates of the present invention release 10 to 60% or more of podophyllotoxin in 24 hours without hydrolase, whereas Comparative Compound 2, which does not have an acid monoamide structure, releases almost no podophyllotoxin even in 24 hours.
- Comparative Compound 2 which does not have an acid monoamide structure, releases almost no podophyllotoxin even in 24 hours.
- the mouse colon cancer colon 26 which was subcultured under the mouse subcutaneously, was made into a block of about 2 mm square and transplanted into the dorsal skin of a female CDF1 mouse using a trocar. Seven days after tumor implantation, the polymer conjugate of the present invention (Compound 1) or a control drug (etoposide, ETP) was administered once into the tail vein of mice. The control is a group not administered with a drug. Compound 1 was dissolved in 5% glucose injection and used. ETP was prepared by diluting lastest injection (Nippon Kayaku Co., Ltd.) with 5% glucose injection.
- the polymer conjugate of the present invention has an anticancer activity superior to that of ETP at a dose (450 mg / kg) at which the same amount of weight loss as ETP (90 mg / kg) occurs.
- the power S was shown.
- Test Example 4 Antitumor activity of compounds 2 and 3
- the mouse colon cancer colon 26 which was subcultured under the mouse subcutaneously, was made into a block of about 2 mm square and transplanted into the dorsal skin of a female CDF1 mouse using a trocar.
- the polymer conjugate of the present invention (Compound 2 and Compound 3) or the control drug (podophyllotoxin, POD) was administered into the tail vein of the mouse.
- Compound 2 and compound 3 were dissolved once in 5% glucose injection and administered once. Controls are groups that do not receive drugs.
- POD was purchased from Sigma, diluted with dimethyl sulfoxide and 5% glucose injection, and administered for 5 consecutive days from the start of administration.
- the major axis (Lmm) and minor axis (Wmm) of the tumor were measured using calipers, and the tumor volume was calculated by (LxW 2 ) / 2. It was shown to.
- the changes in body weight at that time are shown in Table 2 as relative body weights relative to the body weight on the administration start day.
- Control roll Relative thigh volume 1. 00 3. 01 4. 38 6. 52 Relative weight 1. 00 0. 99 0. 97 0. 86
- the polymer conjugate of the present invention has a POD (15 mgZkg / day, administered daily for 5 days) at a dose (75 mgZkg) that causes the same level of weight loss. It has been shown to have superior anticancer activity and to be an anticancer agent.
- FIG. 1 Compound 1 of the present invention (polymer derivative in which etoposide is bound to polyaspartic acid in the block copolymer) and Comparative compound 1 (polymer in which etoposide is bound to polygnoretamic acid in the block copolymer) Derivative) is the ratio of etoposide release to total etoposide binding in PBS solution (pH 7.1, 37 ° C).
- PBS solution pH 7.1, 37 ° C
- “-” indicates the compound 1 of the present invention
- __ indicates the ratio of the release amount of the comparative compound 1.
- FIG. 2 Compound 2 and Compound 3 of the present invention (polymer derivative in which podophyllotoxin is bound to polyaspartic acid of the block copolymer) and Comparative compound 2 (podophyllotoxin to polyglutamic acid of the block copolymer) There percentage of release of Po Zadoff Gray toxin to the total amount of coupling ports Zadoff Gray toxin in PBS solution (P H7.1, 37 ° C) in the polymer derivative) bound.
- ⁇ indicates the ratio of the released amount of Compound 2 of the present invention
- 1 indicates the ratio of the released amount of Compound 3 of the present invention
- 1 indicates the ratio of Comparative Compound 2.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002652656A CA2652656A1 (en) | 2006-05-18 | 2007-05-16 | High-molecular weight conjugate of podophyllotoxins |
US12/226,962 US8940332B2 (en) | 2006-05-18 | 2007-05-16 | High-molecular weight conjugate of podophyllotoxins |
EP07743461A EP2019122A4 (en) | 2006-05-18 | 2007-05-16 | POLYMER CONJUGATE OF PODOPHYL LOTOXIN |
AU2007252678A AU2007252678A1 (en) | 2006-05-18 | 2007-05-16 | Polymer conjugate of podophyllotoxin |
JP2008516621A JP5181347B2 (ja) | 2006-05-18 | 2007-05-16 | ポドフィロトキシン類の高分子結合体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006138509 | 2006-05-18 | ||
JP2006-138509 | 2006-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007135910A1 true WO2007135910A1 (ja) | 2007-11-29 |
Family
ID=38723224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/060026 WO2007135910A1 (ja) | 2006-05-18 | 2007-05-16 | ポドフィロトキシン類の高分子結合体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8940332B2 (ja) |
EP (1) | EP2019122A4 (ja) |
JP (1) | JP5181347B2 (ja) |
KR (1) | KR20090009241A (ja) |
CN (1) | CN101448875A (ja) |
AU (1) | AU2007252678A1 (ja) |
CA (1) | CA2652656A1 (ja) |
RU (1) | RU2447095C2 (ja) |
TW (1) | TW200811225A (ja) |
WO (1) | WO2007135910A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009041570A1 (ja) * | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
WO2009136572A1 (ja) * | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
PL3092124T3 (pl) | 2014-01-10 | 2022-03-21 | Välinge Innovation AB | Sposób wytwarzania fornirowanego elementu |
CN106457781A (zh) | 2014-05-12 | 2017-02-22 | 瓦林格创新股份有限公司 | 生产单板部件的方法以及此类单板部件 |
US10946028B2 (en) | 2015-12-22 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex |
CN113797351B (zh) * | 2021-09-30 | 2023-10-27 | 大连民族大学 | 一步法合成pH响应型的靶向透明质酸-鬼臼毒素前药胶束及其应用 |
CN113750255B (zh) * | 2021-09-30 | 2023-10-31 | 大连民族大学 | 环境响应型透明质酸-鬼臼毒素前药胶束及其制备方法和应用 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6296088A (ja) * | 1985-10-22 | 1987-05-02 | Kanebo Ltd | 抗腫瘍性物質の製法 |
JPS62145093A (ja) * | 1985-12-05 | 1987-06-29 | ブリストル―マイアーズ スクイブ コムパニー | ポドフイロトキシンおよび関連化合物製造用中間体、並びにその製造方法および利用 |
JPS6310789A (ja) * | 1986-07-01 | 1988-01-18 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6323884A (ja) * | 1986-07-17 | 1988-02-01 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6461423A (en) * | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JPS6461422A (en) * | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
JPH10513187A (ja) | 1995-01-30 | 1998-12-15 | エンゾン,インコーポレーテッド | 高分子量のポリマーを基剤とするプロドラッグ |
JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
JP2003509385A (ja) * | 1999-09-13 | 2003-03-11 | ノベックス・コーポレイション | 両親媒性プロドラッグ |
JP2003511349A (ja) * | 1999-04-13 | 2003-03-25 | ファニン バイオサイエンス、インク. | 薬剤担体としてのポリ(ジペプチド) |
JP2003525238A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467587A (en) | 1974-07-11 | 1977-03-16 | Nestle Sa | Preparation of an asparagine or a glutamine |
JPS58135862U (ja) | 1982-03-10 | 1983-09-12 | 三洋電機株式会社 | 密閉型電池 |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
CH667874A5 (fr) | 1985-12-19 | 1988-11-15 | Battelle Memorial Institute | Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments. |
US5182203A (en) | 1989-03-29 | 1993-01-26 | E. I. Du Pont De Nemours And Company | Bifunctional compounds useful in catalyzed reporter deposition |
JP2517760B2 (ja) | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
JP3310000B2 (ja) | 1990-11-07 | 2002-07-29 | 靖久 桜井 | 水溶性高分子抗癌剤及び薬物担持用担体 |
JPH05117385A (ja) | 1991-10-31 | 1993-05-14 | Res Dev Corp Of Japan | ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤 |
KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
JP3270592B2 (ja) | 1992-10-26 | 2002-04-02 | 日本化薬株式会社 | ブロック共重合体−抗癌剤複合体医薬製剤 |
JPH06206830A (ja) | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−薬剤複合体及び高分子ブロック共重合体 |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US5985548A (en) | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
DE4307114A1 (de) | 1993-03-06 | 1994-09-08 | Basf Ag | Verfahren zur Herstellung von Umsetzungsprodukten aus Polyasparaginsäureamid und Aminosäuren und ihre Verwendung |
JP2894923B2 (ja) | 1993-05-27 | 1999-05-24 | 日立造船株式会社 | ウォータージェット式双胴船のジェット水吸込口部構造 |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5571889A (en) | 1994-05-30 | 1996-11-05 | Mitsui Toatsu Chemicals, Inc. | Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same |
JPH0848766A (ja) | 1994-05-30 | 1996-02-20 | Mitsui Toatsu Chem Inc | 重合体及びその製造方法 |
US5552517A (en) | 1995-03-03 | 1996-09-03 | Monsanto Company | Production of polysuccinimide in an organic medium |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
PL189698B1 (pl) | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
DE69734709D1 (de) | 1996-04-15 | 2005-12-29 | Asahi Chemical Ind | Arzneimittelkomplexe enthaltend taxan-verbindungen oder steroiden |
US5877205A (en) | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
WO1998002426A1 (fr) | 1996-07-15 | 1998-01-22 | Kabushiki Kaisha Yakult Honsha | Derives de taxane et medicaments les contenant |
DE69725877T2 (de) | 1996-08-26 | 2004-07-22 | Transgene S.A. | Kationische lipid-nukleinsäure komplexe |
GB9625895D0 (en) | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
DK0879604T3 (da) | 1997-05-09 | 2003-08-04 | Deutsches Krebsforsch | Konjugat omfattende en folinsyreantagonist og en bærer |
EP1037649B1 (en) | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6824766B2 (en) | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
JPH11335267A (ja) | 1998-05-27 | 1999-12-07 | Nano Career Kk | 水難溶性薬物を含有するポリマーミセル系 |
IN191203B (ja) | 1999-02-17 | 2003-10-04 | Amarnath Prof Maitra | |
US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6623730B1 (en) | 1999-09-14 | 2003-09-23 | Tepha, Inc. | Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
JP2003511423A (ja) | 1999-10-12 | 2003-03-25 | セル・セラピューティックス・インコーポレーテッド | ポリグルタメート−治療薬コンジュゲートの製造 |
US20030054977A1 (en) | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
JP3523821B2 (ja) | 2000-02-09 | 2004-04-26 | ナノキャリア株式会社 | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
MXPA02009082A (es) | 2000-03-17 | 2003-12-11 | Cell Therapeutics Inc | Conjugados de acido poliglutamico-camptotecina y metodos de preparacion. |
US20020161062A1 (en) | 2001-11-06 | 2002-10-31 | Biermann Paul J. | Structure including a plurality of cells of cured resinous material, method of forming the structure and apparatus for forming the structure |
ATE541587T1 (de) | 2000-06-02 | 2012-02-15 | Eidgenoess Tech Hochschule | Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen |
JP2002069184A (ja) | 2000-06-12 | 2002-03-08 | Mitsui Chemicals Inc | 重合体及びその製造方法 |
AU2001296215A1 (en) | 2000-07-17 | 2002-01-30 | Oxi-Gene, Inc. | Efficient method of synthesizing combretastatin a-4 prodrugs |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
ATE437647T1 (de) | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
WO2002065988A2 (en) | 2001-02-20 | 2002-08-29 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
EP1361895B1 (en) | 2001-02-20 | 2007-11-14 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
PL222061B1 (pl) | 2001-06-20 | 2016-06-30 | Nippon Kayaku Kk | Sposób produkcji kopolimeru blokowego, nośnik polimerowy oraz polimerowy preparat farmaceutyczny |
EP1438281A4 (en) | 2001-10-26 | 2006-04-26 | Oxigene Inc | FUNCTIONALIZED STYLENE DERIVATIVES AS IMPROVED MEDIUM-TERM MEDICAL DEVICES |
US7247734B2 (en) | 2001-12-21 | 2007-07-24 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
PL373567A1 (en) | 2002-03-01 | 2005-09-05 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
CN100475269C (zh) | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
RS84904A (en) | 2002-03-26 | 2006-12-15 | Bany Pharmaceutical Co.Ltd. | Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP2003342167A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | カンプトテシン誘導体の製剤およびその調製方法 |
JP4270485B2 (ja) | 2002-05-28 | 2009-06-03 | 第一三共株式会社 | タキサン類の還元方法 |
JP2004010479A (ja) | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
BRPI0407403B1 (pt) | 2003-02-11 | 2022-07-19 | Cancer Research Technology Ltd | Compostos de isoxazol e composição farmacêutica |
ATE483476T1 (de) | 2003-03-20 | 2010-10-15 | Nippon Kayaku Kk | Micellen-zubereitung mit schwer wasserlöslichem anti-krebsmittel und neuem blockcopolymer |
JP2006521367A (ja) | 2003-03-26 | 2006-09-21 | 株式会社Lttバイオファーマ | ターゲッティングと徐放を目的とした静脈注射用ナノ粒子 |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
JP2005051922A (ja) | 2003-07-29 | 2005-02-24 | Yokogawa Electric Corp | 電力供給システム及び電力供給方法 |
US20070004674A1 (en) | 2003-08-22 | 2007-01-04 | Kyowa Hakko Kogyo Co. Ltd. | Remedy for diseases associated with immunoglobulin gene translocation |
CA2542834C (en) | 2003-10-21 | 2012-04-24 | Igf Oncology, Llc | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
CN1930190B (zh) | 2004-01-07 | 2011-04-20 | 生化学工业株式会社 | 透明质酸衍生物及含有其的药剂 |
CA2581125C (en) | 2004-09-22 | 2013-04-23 | Nippon Kayaku Kabushiki Kaisha | Modified poly(ethylene oxide-amino acid) copolymer, micelle preparation, and anticancer agent containing the same |
JP2006120914A (ja) | 2004-10-22 | 2006-05-11 | Matsushita Electric Ind Co Ltd | 部品吸着ノズル、並びに部品実装装置及び部品実装方法 |
ATE497034T1 (de) | 2004-11-16 | 2011-02-15 | Hyperion Catalysis Int | Verfahren zur herstellung von trägerkatalysatoren aus metallbeladenen kohlenstoffnanoröhrchen |
ES2399241T3 (es) | 2004-11-18 | 2013-03-26 | Synta Pharmaceuticals Corporation | Compuestos de triazol que modulan la actividad de HSP90 |
EP1857446B1 (en) | 2005-03-09 | 2013-05-01 | Nippon Kayaku Kabushiki Kaisha | Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer |
US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
CN101137700B (zh) | 2005-03-09 | 2012-07-18 | 东丽株式会社 | 微粒及医药组合物 |
JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
JPWO2006115293A1 (ja) | 2005-04-22 | 2008-12-18 | 国立大学法人 東京大学 | pH応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 |
EP1881020B1 (en) | 2005-05-11 | 2010-08-11 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of cytidine metabolic antagonist |
CN101175490B (zh) | 2005-05-12 | 2011-06-08 | 尼普洛株式会社 | 循环障碍改善剂 |
EP2382995A3 (en) | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
JP4975297B2 (ja) | 2005-10-20 | 2012-07-11 | 山佐株式会社 | スロットマシン |
CN1800238A (zh) | 2005-12-05 | 2006-07-12 | 中国科学院长春应用化学研究所 | 有生物功能的脂肪族聚酯—聚氨基酸共聚物及合成方法 |
JP2007182407A (ja) | 2006-01-10 | 2007-07-19 | Medgel Corp | 徐放性ハイドロゲル製剤 |
JP2007191643A (ja) | 2006-01-20 | 2007-08-02 | Mitsui Chemicals Inc | 生体への定着性が付与されたポリアミノ酸誘導体 |
WO2007111211A1 (ja) | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
JPWO2008010463A1 (ja) | 2006-07-19 | 2009-12-17 | 日本化薬株式会社 | コンブレタスタチン類の高分子結合体 |
JP4587994B2 (ja) | 2006-08-10 | 2010-11-24 | 三菱電機株式会社 | 回路遮断器 |
JP5548364B2 (ja) | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
EP2080779B1 (en) | 2006-11-06 | 2016-05-18 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
JP5548365B2 (ja) | 2006-11-08 | 2014-07-16 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
JP5349318B2 (ja) | 2007-09-28 | 2013-11-20 | 日本化薬株式会社 | ステロイド類の高分子結合体 |
EP2258397B1 (en) | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of physiologically active substance |
EP2284209B1 (en) | 2008-05-08 | 2016-08-31 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
KR20110020779A (ko) | 2008-05-23 | 2011-03-03 | 나노캐리어 가부시키가이샤 | 도세탁셀 고분자 유도체 및 그 제조 방법 및 그 용도 |
EP2431403B1 (en) | 2009-05-15 | 2016-09-28 | Nipponkayaku Kabushikikaisha | Polymer conjugate of bioactive substance having hydroxy group |
TW201304805A (zh) | 2010-11-17 | 2013-02-01 | Nippon Kayaku Kk | 新穎之胞核苷系代謝拮抗劑之高分子衍生物 |
-
2007
- 2007-05-16 US US12/226,962 patent/US8940332B2/en not_active Expired - Fee Related
- 2007-05-16 CN CNA2007800177809A patent/CN101448875A/zh active Pending
- 2007-05-16 KR KR1020087027893A patent/KR20090009241A/ko not_active Application Discontinuation
- 2007-05-16 CA CA002652656A patent/CA2652656A1/en not_active Abandoned
- 2007-05-16 JP JP2008516621A patent/JP5181347B2/ja not_active Expired - Fee Related
- 2007-05-16 WO PCT/JP2007/060026 patent/WO2007135910A1/ja active Application Filing
- 2007-05-16 RU RU2008149932/04A patent/RU2447095C2/ru not_active IP Right Cessation
- 2007-05-16 AU AU2007252678A patent/AU2007252678A1/en not_active Abandoned
- 2007-05-16 EP EP07743461A patent/EP2019122A4/en not_active Withdrawn
- 2007-05-17 TW TW096117516A patent/TW200811225A/zh unknown
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6296088A (ja) * | 1985-10-22 | 1987-05-02 | Kanebo Ltd | 抗腫瘍性物質の製法 |
JPS62145093A (ja) * | 1985-12-05 | 1987-06-29 | ブリストル―マイアーズ スクイブ コムパニー | ポドフイロトキシンおよび関連化合物製造用中間体、並びにその製造方法および利用 |
JPS6310789A (ja) * | 1986-07-01 | 1988-01-18 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6323884A (ja) * | 1986-07-17 | 1988-02-01 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6461423A (en) * | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JPS6461422A (en) * | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
JPH10513187A (ja) | 1995-01-30 | 1998-12-15 | エンゾン,インコーポレーテッド | 高分子量のポリマーを基剤とするプロドラッグ |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
JP2003511349A (ja) * | 1999-04-13 | 2003-03-25 | ファニン バイオサイエンス、インク. | 薬剤担体としてのポリ(ジペプチド) |
JP2003509385A (ja) * | 1999-09-13 | 2003-03-11 | ノベックス・コーポレイション | 両親媒性プロドラッグ |
JP2003525238A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
WO2009041570A1 (ja) * | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
JPWO2009136572A1 (ja) * | 2008-05-08 | 2011-09-08 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
JP5366940B2 (ja) * | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
WO2009136572A1 (ja) * | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
Also Published As
Publication number | Publication date |
---|---|
JP5181347B2 (ja) | 2013-04-10 |
TW200811225A (en) | 2008-03-01 |
AU2007252678A1 (en) | 2007-11-29 |
EP2019122A1 (en) | 2009-01-28 |
US20090162313A1 (en) | 2009-06-25 |
CN101448875A (zh) | 2009-06-03 |
JPWO2007135910A1 (ja) | 2009-10-01 |
RU2008149932A (ru) | 2010-06-27 |
RU2447095C2 (ru) | 2012-04-10 |
CA2652656A1 (en) | 2007-11-29 |
US8940332B2 (en) | 2015-01-27 |
KR20090009241A (ko) | 2009-01-22 |
EP2019122A4 (en) | 2009-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007135910A1 (ja) | ポドフィロトキシン類の高分子結合体 | |
JP5249016B2 (ja) | タキサン類の高分子結合体 | |
JP4745664B2 (ja) | カンプトテシン類の高分子誘導体 | |
JP5687899B2 (ja) | 生理活性物質の高分子結合体 | |
JP5544357B2 (ja) | 水酸基を有する生理活性物質の高分子結合体 | |
JP5349318B2 (ja) | ステロイド類の高分子結合体 | |
AU2006245107B2 (en) | Polymeric derivative of cytidine metabolic antagonist | |
WO2008010463A1 (fr) | Conjugué polymère d'une combrétastatine | |
JP5856069B2 (ja) | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780017780.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07743461 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2008516621 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007743461 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027893 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2652656 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007252678 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008149932 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12226962 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2007252678 Country of ref document: AU Date of ref document: 20070516 Kind code of ref document: A |